Choroidal Vasculature in Bietti Crystalline Dystrophy With \textit{CYP4V2} Mutations and in Retinitis Pigmentosa With \textit{EYS} Mutations

Takako Hirashima, Manabu Miyata, Kenji Ishihara, Tomoko Hasegawa, Masako Sugahara, Ken Ogino, Munemitsu Yoshikawa, Masayuki Hata, Yoshimasa Kuroda, Yuki Muraoka, Sotaro Ooto, and Nagahisa Yoshimura

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan

\textbf{Correspondence:} Manabu Miyata, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Shogoin Kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan; miyata@kuhp.kyoto-u.ac.jp.

Submitted: January 18, 2017
Accepted: July 4, 2017

\textbf{PURPOSE.} We compare the choroidal vascular area between Bietti crystalline dystrophy (BCD) patients with \textit{CYP4V2} mutations, retinitis pigmentosa (RP) patients with \textit{EYS} mutations, and normal controls, and investigate the correlation between choroidal vascular area and associated parameters.

\textbf{METHODS.} This prospective case-series study included consecutive nine eyes of nine BCD patients with \textit{CYP4V2} mutations (BCD group), 16 eyes of 16 RP patients with \textit{EYS} mutations (\textit{EYS}-RP group), and 16 eyes of 16 normal volunteers matched for age and axial length (control group). Using swept-source optical coherence tomography, we obtained en face images of the choroidal vasculature at the midpoint of the choriocapillaris layer—Sattler’s layer (inner choroid) and Haller’s layer (outer choroid). After binarization, we compared the inner and outer choroidal vascular areas among the three groups and identified associated factors.

\textbf{RESULTS.} The outer choroidal vascular area was $43.34 \pm 5.76\%$, $53.73 \pm 4.92\%$, and $52.80 \pm 4.10\%$ in the BCD, \textit{EYS}-RP, and control groups, respectively. This value was significantly smaller in the BCD group than in the \textit{EYS}-RP and control groups ($P < 0.001$ in both; no significant difference between the \textit{EYS}-RP and control groups). In the BCD group, the outer choroidal vascular area was correlated strongly with the subfoveal inner choroidal thickness ($P = 0.001$, $r = 0.91$, respectively). The inner choroidal vasculature could not be identified in eight of nine eyes in the BCD group.

\textbf{CONCLUSIONS.} The outer choroidal vascular narrowing might progress with the inner choroidal thinning in BCD, and the inner choroidal vasculature might be extinguished in advanced-stage BCD. Our findings may help to clarify the etiology of BCD.

Keywords: choroidal vasculature, Bietti crystalline dystrophy, retinitis pigmentosa, \textit{CYP4V2}, \textit{EYS}

Bietti crystalline dystrophy (BCD) is a rare retinal dystrophy characterized by the presence of shiny yellow deposits on the cornea and posterior pole of the retina. The symptoms of BCD, including night blindness and progressive constriction of the visual field, are similar to those of retinitis pigmentosa (RP). BCD is caused by mutations of \textit{CYP4V2}. On the other hand, more than 50 causative genes for nonsyndromic RP have been identified. A major causative gene for RP is \textit{EYS} in the Japanese, Spanish, British, Chinese, Israeli, and Palestinian populations. The main sites of expression of \textit{CYP4V2} in the eye are the RPE and choroid whereas \textit{EYS} is expressed mainly in the outer segments of the photoreceptors. A previous study using enhanced depth imaging spectral domain optical coherence tomography (SD-OCT) showed choroidal thinning in a BCD patient. Furthermore, another previous report using swept-source optical coherence tomography (SS-OCT) identified differences in the patterns of pathologic damage between BCD patients with \textit{CYP4V2} mutations and RP patients with \textit{EYS} mutations, that is, the choroidal damage was more severe in the former than in the latter group. However, that study only estimated choroidal thickness and did not estimate the difference in the choroidal vasculature.

It is difficult to visualize the entire choroidal structure because of the low penetration and high backscattering at the level of the RPE of SD-OCT, which is used widely in clinical examination. SS-OCT, which has a longer wavelength than SD-OCT, allows a three-dimensional (3D) high-contrast image of the choroid to be obtained. Further algorithms have been developed for SS-OCT that allowed en face imaging of the choroid. Recently, Kuroda et al. reported an objective increase in choroidal vascular area in eyes with central serous chorioretinopathy using en face images obtained with SS-OCT. Their methods enabled us to investigate the choroidal vascular area of BCD patients with \textit{CYP4V2} mutations.

We compared objectively the choroidal vascular areas in BCD patients with \textit{CYP4V2} mutations with RP patients with \textit{EYS} mutations and normal controls using en face SS-OCT imaging and investigated the correlation between the choroidal vascular area and its associated parameters.
METHODS

This prospective, observational case-series study was approved by the ethics committee at Kyoto University Graduate School of Medicine (Kyoto, Japan). All study protocols adhered to the tenets of the Declaration of Helsinki. The nature of the study and possible risks and benefits of participation were explained to all study candidates. All subjects who agreed to participate provided written informed consent.

Subjects

We recruited consecutive patients with degenerative retinal disease or retinal dystrophy who visited the Department of Ophthalmology and Visual Science at Kyoto University Graduate School of Medicine between September 2015 and October 2016. All patients provided blood samples for detection of gene mutations and underwent a comprehensive ophthalmologic examination, including autorefractometry; measurement of best-corrected visual acuity (VA) using a decimal VA chart (Landolt chart), and axial length (AL) using an IOL Master (Carl Zeiss Meditec, Inc., Dublin, CA, USA); indirect ophthalmoscopy; slit-lamp biomicroscopy; color fundus photography and fundus autofluorescence using an Optos device (Optos PLC, Dunfermline, UK, Fig. 1); SD-OCT (Spectralis HRA+OCT; Heidelberg Engineering, Heidelberg, Germany); and calculation of the mean deviation (MD) value with a Humphrey field analyzer with the 10-2 Swedish Interactive Threshold Algorithm standard program.19 SS-OCT (DRI OCT-1; Topcon Corp., Tokyo, Japan; Fig. 1) also was performed. A clinical diagnosis of BCD or RP was made based on the above comprehensive ophthalmologic examinations by retinal specialists.

The inclusion criteria were as follows: BCD with homozygous or compound heterozygous mutations of CYP4V2 or RP.
with homozygous or compound heterozygous mutations of EYS, and clear image quality on SS-OCT. The exclusion criteria were presence of other ocular diseases except for refractive errors, cataract, or pseudophakia, and AL ≥ 26.0 mm. When both eyes in one patient met the eligibility criteria, the right eye was selected for analysis. We also recruited healthy volunteers and patients with unilateral retinal disease, including epiretinal membrane and vitreomacular traction syndrome. We studied age-, sex-, and AL-matched healthy eyes (VA ≥ 20/20) for comparison with those of BCD or RP patients.

**Images Obtained Using SS-OCT**

Trained examiners performed the SS-OCT examinations after pupil dilation. They achieved pupil centration during the scan by using an internal fixation target that was confirmed using the camera built into the SS-OCT system. Each 3D volumetric scan covered an area of 3 × 3 mm² and was centered on the fovea. The 3D 3 × 3 mm² volumetric scans consisted of 512 (horizontal) × 256 (vertical) A-scans. In each B-scan of the 3D data set, the outer surface of the Bruch’s membrane (BM) line was determined automatically by the software, and manual corrections were made as necessary using the built-in segmentation modifying tool. En face images were reconstructed automatically from the 3D data set using the software developed by Topcon Corporation.18 En face images of the choroid were taken at varying depths every 2.6 μm from the BM, and were flattened at the level of the BM (Fig. 1). In Figure 2, the en face images show the vascular lumen as a black region and the vascular wall and choroidal stroma as a white region.

**Measurement of Subfoveal Choroidal Thickness and Foveal Thicknesses**

Horizontal B-scan images through the fovea obtained by SS-OCT were used to measure the subfoveal choroidal thickness and foveal thickness. Two investigators (T. Hirashima and M. Miyata) manually measured these thicknesses using the built-in caliper tool. The outermost highly reflective retinal band comprises the RPE and BM.25 Foveal thickness was defined as the distance between the vitreoretinal interface and the outer border of the RPE/BM complex at the fovea. Subfoveal choroidal thickness was defined as the distance between the outer border of the RPE/BM complex and the choriocapillaris layer and the Sattler’s layer, which corresponds to the Haller’s layer (large choroidal vessel layer) thickness. The ratio of the subfoveal inner against the total choroidal thickness (%) was calculated. The mean measurements obtained by the two investigators were used for the analysis.

**Measurement of Choroidal Vascular Area**

To evaluate the area of the choroidal vasculature, we analyzed en face images at the level of the inner and outer choroid. Each en face image was created by extracting information from 3D raster scans at every 2.6-μm depth. We analyzed the choroidal vascular area from the en face images through the midpoints of the subfoveal inner and subfoveal outer choroid. The area of the choroidal vasculature in the adopted image was calculated automatically using ImageJ software (Wayne
Table 1. Characteristic of the Study Population

<table>
<thead>
<tr>
<th></th>
<th>BCD Group</th>
<th>EYS-RP Group</th>
<th>Control Group</th>
<th>BCD vs. EYS-RP</th>
<th>BCD vs. Control</th>
<th>EYS-RP vs. Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>n, eyes (subjects)</td>
<td>9 (9)</td>
<td>16 (16)</td>
<td>16 (16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female sex, eyes (%)</td>
<td>6 (67)</td>
<td>10 (65)</td>
<td>12 (75)</td>
<td>0.98</td>
<td>0.91</td>
<td>0.74</td>
</tr>
<tr>
<td>Age, y</td>
<td>58.2 ± 4.6</td>
<td>52.4 ± 11.4</td>
<td>55.6 ± 14.2</td>
<td>0.46</td>
<td>0.85</td>
<td>0.72</td>
</tr>
<tr>
<td>AL, mm</td>
<td>23.96 ± 0.92</td>
<td>24.10 ± 1.23</td>
<td>24.09 ± 1.03</td>
<td>0.95</td>
<td>0.95</td>
<td>1.00</td>
</tr>
<tr>
<td>LogMAR VA</td>
<td>0.37 ± 0.57</td>
<td>0.34 ± 0.52</td>
<td>-</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MD value, dB</td>
<td>-28.06 ± 9.54</td>
<td>-16.80 ± 10.69</td>
<td>-</td>
<td>0.021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lens status, phakic eyes</td>
<td>8</td>
<td>12</td>
<td>12</td>
<td>0.72</td>
<td>0.72</td>
<td>1.00</td>
</tr>
<tr>
<td>Foveal thickness, μm</td>
<td>125.4 ± 52.2</td>
<td>171.0 ± 44.1</td>
<td>195.8 ± 23.8</td>
<td>0.02*</td>
<td>&lt;0.001*</td>
<td>0.19</td>
</tr>
</tbody>
</table>

Rasband, National Institutes of Health [NIH], Bethesda, MD, USA; available in the public domain at http://rsb.info.nih.gov/ij/index.html), according to a previous report. Briefly, the command path of Image > Adjust > Threshold > Auto in ImageJ was used to distinguish the vasculature and choroidal stroma, and the adopted images were binarized using the Otsu method, which is an automatic threshold selection from gray-level histograms (Fig. 2). Next, the area of the presumed vascular lumen portion was calculated in pixels using the command path of Analyze > Measure in ImageJ. In our study, the choroidal vascular area in the adopted images was defined as the portion of the vascular lumen area in the whole scan area in the inner and outer choroid, and is expressed as a percentage.

Statistical Analysis

data are presented as mean ± SD where applicable. BCD group, eyes of BCD patients with CYP4V2 mutations; EYS-RP group, eyes of RP patients with EYS mutations; Control group, healthy eyes; Inner choroid, from the outer border of the RPE and BM complex to the border between the medium and large vessel layers; Outer choroid, from the border between the medium and large vessel layers to the choriocapillaris interface.

The study included nine eyes of nine Japanese BCD patients with CYP4V2 mutations (six women; BCD group), 16 eyes of 16 Japanese RP patients with EYS mutations (10 women; EYS-RP group), and 16 healthy eyes of 16 Japanese volunteers (12 women; control group). There were no blood relationships between any of the patients. The characteristics of the study population are shown in Table 1, and the clinical characteristics of the BCD and EYS-RP groups are shown in Table 2. The age of the subjects was 58.2, 52.4 ± 11.4, and 55.6 ± 14.2 years in the BCD, EYS-RP, and control groups, respectively; 6 (67%), 10 (63%), and 12 (75%) eyes, respectively, were from female subjects; and the AL was 23.96 ± 0.92, 24.10 ± 1.23, and 24.09 ± 1.03 mm, respectively. There were no statistically significant differences in subject age, sex, or AL among the three groups. The logMAR VA in the BCD group was not significantly different from the EYS-RP group (0.37 ± 0.57 vs. 0.34 ± 0.52, P = 0.91). However, the MD value in the BCD group was significantly smaller than that in the EYS-RP group (−28.06 ± 9.54 vs. −16.80 ± 10.69 dB, P = 0.02).

Subfoveal Choroidal and Foveal Thicknesses

The subfoveal choroidal thickness was 102.9 ± 26.7, 208.5 ± 52.9, and 237.8 ± 61.8 μm in the BCD, EYS-RP, and control groups, respectively. The subfoveal choroidal thickness in the BCD group was significantly smaller than that in the EYS-RP (P < 0.001) and control (P < 0.001) groups, while there was no significant difference between the EYS-RP and control groups (P = 0.27). The subfoveal inner choroidal thickness was 25.4 ± 10.2, 76.8 ± 25.3, and 80.6 ± 21.7 μm in the BCD, EYS-RP, and
control groups, respectively. The ratio of the subfoveal inner
against total choroidal thickness in the BCD group was
significantly smaller than that in the EYS-RP (P < 0.001) and
control (P = 0.002) groups. Foveal thickness in the BCD group
was significantly smaller than that in the EYS-RP (P = 0.02) and
control (P < 0.001) groups. The ICC (2, 1) values for the
subfoveal choroidal, foveal, and subfoveal inner choroidal
thickness measurements were 0.981, 0.983, and 0.964,
respectively.

**Choroidal Vascular Area**

The outer choroidal vascular area on en face images was
analyzable in all subjects. The area was 43.54% ± 5.76%,
53.73% ± 4.92%, and 52.80% ± 4.10% in the BCD, EYS-RP, and
control groups, respectively. The outer choroidal vascular area
in the BCD group was significantly smaller than that in the EYS-
RP (P < 0.001) and control (P < 0.001) groups, but was not
significantly different between the EYS-RP and control (P = 0.85)
groups. Table 3 shows the correlations between the outer choroidal vascular area and other parameters, respect-
ively. In the BCD group, the outer choroidal vascular area was
correlated strongly with the subfoveal inner choroidal thick-
ness (P = 0.001, r = 0.91). The inner choroidal vasculature on
en face images could not be identified in eight of nine eyes in the
BCD group. Therefore, the statistical analysis in the BCD
group did not include measurements of the inner choroidal
vasculature. When the cutoff value for the outer choroidal
vascular area was set at 46.67%, we could distinguish patients
in the BCD group from those in the EYS-RP group with a
specificity of 100% and a sensitivity of 77.8% (Fig. 3). From the
AUROC curve, the best sensitivity–specificity balance achieved
was 0.944.

**DISCUSSION**

We found that the subfoveal choroidal thickness and the outer
choroidal vascular area were smaller in BCD patients with
CYP4V2 mutations than in age-, sex-, AL-, and logMAR VA-
matched RP patients with EYS mutations or age-, sex-, and AL-
matched healthy controls. The difference in the degree of
choroidal vascular damage between the BCD and EYS-RP patients could be accounted for by the difference in
expression sites between CYP4V2 and EYS. Furthermore,
among the studied parameters, the outer choroidal vascular
area was correlated strongly with the inner choroidal
thickness in BCD patients. This suggests that the outer choroidal vascular narrowing might progress with the inner
choroidal atrophy in BCD. Furthermore, the inner choroidal
vasculature could not be identified in most of the BCD
patients. These findings may partly help to clarify the etiology
of BCD.

The choroid is a highly vascular tissue located beneath the
retina, and has an important role in providing the retina with
nutrients. Although choroidal disorders do not directly affect
visual function, long-term deficiencies in nutrient supply from
the choroidal vessels can lead to retinal damage. Our structural findings, an increased probability of the absence of the inner choroidal vasculature and increased outer choroidal vascular narrowing in BCD patients, suggested that the choroidal dysfunction of the outer retina may be more severe in BCD than EYS-RP patients. Furthermore, we reported previously that the photoreceptors in BCD patients with CYP4V2 mutations were relatively preserved despite severe disease progression.24 These results suggested that the retinal damage is delayed compared to the choroidal damage in BCD patients. Further research investigating blood flow dynamics in BCD patients is necessary.

Our study showed the significance of measuring the inner choroidal thickness, which to our knowledge has not been reported previously. Although the outer choroidal vascular area was not correlated with visual function including the VA and MD value, it was correlated strongly with the subfoveal inner choroidal thickness in BCD patients (r = 0.91). This implies that the inner choroidal thickness measured by B-scans could provide information on the state of the outer choroidal vasculature in BCD patients without having to estimate the vascular area. If the outer choroidal vascular area represents disease progression stage, the degree of the inner choroidal thinning could be used conveniently to classify the stage in BCD. Further research including various stages is necessary.

The ratio of the subfoveal inner against total choroidal thickness was significantly smaller in BCD than EYS-RP patients and healthy controls, which indicates that the degree of choroidal atrophy is higher in the inner choroid in BCD patients. To our knowledge, this finding has not been reported previously. Although the outer choroidal vascular area was not correlated with visual function including the VA and MD value, it was correlated strongly with the subfoveal inner choroidal thickness in BCD patients (r = 0.91). This implies that the inner choroidal thickness measured by B-scans could provide information on the state of the outer choroidal vasculature in BCD patients without having to estimate the vascular area. If the outer choroidal vascular area represents disease progression stage, the degree of the inner choroidal thinning could be used conveniently to classify the stage in BCD. Further research including various stages is necessary.

The ratio of the subfoveal inner against total choroidal thickness was significantly smaller in BCD than EYS-RP patients and healthy controls, which indicates that the degree of choroidal atrophy is higher in the inner choroid in BCD patients. To our knowledge, this finding has not been reported previously. Although the outer choroidal vascular area was not correlated with visual function including the VA and MD value, it was correlated strongly with the subfoveal inner choroidal thickness in BCD patients (r = 0.91). This implies that the inner choroidal thickness measured by B-scans could provide information on the state of the outer choroidal vasculature in BCD patients without having to estimate the vascular area. If the outer choroidal vascular area represents disease progression stage, the degree of the inner choroidal thinning could be used conveniently to classify the stage in BCD. Further research including various stages is necessary.

The ratio that we determined may allow for differential diagnoses. Further research to compare the ratio between the two diseases is necessary.

Indocyanine green angiography is a standard modality for assessing choroidal vasculature, but cannot be used to assess individual layers. However, our study compared two different diseases with obviously different choroidal thickness.35 Therefore, we adopted a method using en face images to analyze each layer of the choroidal vasculature separately. Furthermore, we modified the method of the previous study to analyze en face images through the midpoint of the total choroid; that is, we first assessed the subfoveal inner choroidal thickness in each group, and then analyzed en face images through each midpoint of the inner and outer choroid. We believe that our method is suitable for analyzing the choroidal

| TABLE 3. Correlation Between Outer Choroidal Vascular Area and Other Parameters in BCD and EYS-RP Groups |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| **BCD Group, n = 9** | **EYS-RP Group, n = 16** | **Control Group, n = 16** |
| Age | 0.36 | 0.02* | 0.80 |
| Sex | 0.64 | 0.08 | 0.023 |
| AL | 0.18 | 0.85 | 0.76 |
| LogMAR VA | 0.55 | 0.73 | - |
| MD value | 0.14 | 0.42 | - |
| Lens status | 0.48 | 0.73 | 0.12 |
| Foveal thickness | 0.23 | 0.55 | 0.55 |
| **Total** | **0.15** | **0.59** | **0.02** |
| **Inner** | **0.001** | **0.17** | **0.45** |
| **Outer** | **0.59** | **0.93** | **0.01** |
| **Subfoveal choroidal thickness** | | | |
| **Total** | | | |
| **Inner** | | | |
| **Outer** | | | |

BCD group, eyes of BCD patients with CYP4V2 mutations; EYS-RP group, eyes of RP patients with EYS mutations; Control group, healthy eyes; Inner choroid, from the outer border of the RPE and BM complex to the border between the medium and large vessel layers; Outer choroid, from the border between the medium and large vessel layers to the choriocapillaris interface.

* Statistically significant (P < 0.05).
vascular area, and in particular, to compare different diseases with different degrees of choroidal atrophy.

Our study has some limitations. The first limitation is that the sample size in the BCD group was small, reflecting the fact that BCD is a rare disease. However, it is unlikely that the inclusion of a larger sample size would have changed our results, given the marked difference between the BCD and EYS-RP groups. Second, we could not detect the inner choroidal vasculature in en face images in most of the BCD patients, either because the inner choroidal vasculature was too thin to be resolved on the images, or the vasculature of the choriocapillaris layer, Sattler’s layer, was lost. A previous study using fluorescein angiography indicated the probability of choriocapillaris atrophy in advanced-stage BCD. The development of modalities with high resolution and the corresponding analytical algorithms would allow us to clarify whether the inner choroidal vasculature is present in BCD patients. Third, there might be a difference of disease severity between the two groups. Further research with matched MD values is necessary.

In conclusion, the outer choroidal vascular area in BCD patients with CYP4V2 mutations is smaller than that in RP patients with EYS mutations and in healthy controls, and the inner choroidal vasculature might be extinguished in advanced-stage BCD patients. Furthermore, the outer choroidal vascular area, and in particular, to compare different diseases with different degrees of choroidal atrophy.

Our study has some limitations. The first limitation is that the sample size in the BCD group was small, reflecting the fact that BCD is a rare disease. However, it is unlikely that the inclusion of a larger sample size would have changed our results, given the marked difference between the BCD and EYS-RP groups. Second, we could not detect the inner choroidal vasculature in en face images in most of the BCD patients, either because the inner choroidal vasculature was too thin to be resolved on the images, or the vasculature of the choriocapillaris layer, Sattler’s layer, was lost. A previous study using fluorescein angiography indicated the probability of choriocapillaris atrophy in advanced-stage BCD. The development of modalities with high resolution and the corresponding analytical algorithms would allow us to clarify whether the inner choroidal vasculature is present in BCD patients. Third, there might be a difference of disease severity between the BCD and EYS-RP groups. Further research with matched MD values is necessary.

In conclusion, the outer choroidal vascular area in BCD patients with CYP4V2 mutations is smaller than that in RP patients with EYS mutations and in healthy controls, and the inner choroidal vasculature might be extinguished in advanced-stage BCD patients. Furthermore, the outer choroidal vascular area, and in particular, to compare different diseases with different degrees of choroidal atrophy.

Acknowledgments

The authors thank Akitaka Tsujikawa, Akio Oishi, and Maho Oishi for their helpful discussion regarding our methodology.

Supported in part by a grant-in-aid for scientific research (No. 26861451) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project for Developing Innovation Systems from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan. None of these organizations had any role in the design or conduct of this research.

Disclosure: T. Hirashima, None; M. Miyata, None; K. Ishihara, None; T. Hasegawa, None; M. Sugahara, None; K. Ogino, None; M. Yoshikawa, None; M. Hata, None; Y. Kuroda, None; Y. Muraoka, None; S. Ooto, Alcon Japan (F); N. Yoshimura, None; K. Ogino, None; Alcon Japan (F); T. Hirashima, None; M. Miyata, None; K. Ishihara, None; T. Hasegawa, None; M. Sugahara, None; K. Ogino, None; M. Yoshikawa, None; M. Hata, None; Y. Kuroda, None; Y. Muraoka, None; S. Ooto, Alcon Japan (F); N. Yoshimura, None; K. Ogino, None; Alcon Japan (F). The authors thank Akitaka Tsujikawa, Akio Oishi, and Maho Oishi for their helpful discussion regarding our methodology.

Supported in part by a grant-in-aid for scientific research (No. 26861451) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project for Developing Innovation Systems from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan. None of these organizations had any role in the design or conduct of this research.

Disclosure: T. Hirashima, None; M. Miyata, None; K. Ishihara, None; T. Hasegawa, None; M. Sugahara, None; K. Ogino, None; M. Yoshikawa, None; M. Hata, None; Y. Kuroda, None; Y. Muraoka, None; S. Ooto, Alcon Japan (F); N. Yoshimura, Topcon Corporation (F); Nidek (F), Canon (F)

References


